Medtronic Inc (MDT) 76.48 $MDT
Seeking Alpha's Biotech Weekly: AbbVie - Pharmacyclitics, Orexigen Confusion, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), ARWR: 7.75 (-0.19), SPHS: 0.70 (-0.03), BSX: 16.56 (-0.41), MDVN: 126.55 (-0.53), JNJ: 100.11 (-2.41), AAC: 29.30 (-2.80), ABBV: 55.64 (-1.22), SNY: 47.42 (-0.94), SMMT: 10.29 (+0.10), ARNA: 4.32 (+0.09), XLRN: 40.55 (-0.79), MNK: 121.33 (-0.37), AQXP: 10.49 (+0.43), PFE: 33.97 (-0.50), AMGN: 154.88 (-4.72), GSK: 46.73 (-0.87), BMY: 65.12 (-0.93), MNKD: 5.47 (-0.26), CELG: 118.03 (-2.68), OREX: 7.10 (-0.91), PODD: 32.24 (+0.26), GERN: 3.50 (-0.28), TEVA: 56.40 (-0.11), TCON: 17.57 (+0.36), NVS: 97.46 (-1.49)
Stock Market News for March 06, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 9:10AM CST
Markets snapped a two-day losing streak on Thursday, somewhat boosted by the ECB announcing a trillion-dollar stimulus plan that will kick off on Monday
BIIB: 417.63 (-7.98), JNJ: 100.11 (-2.41), PCYC: 254.56 (+0.34), ADP: 86.00 (-0.75), MDT: 76.48 (-2.02), GILD: 101.81 (-1.61), ABBV: 55.64 (-1.22), BMY: 65.12 (-0.93)
Medtronic Positive on Covidien Integration, Potential Synergy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 05, 1:30PM CST
On Mar 4, 2015, we issued an updated research report on Medtronic, Inc. (MDT).
CSII: 36.10 (-1.36), MDT: 76.48 (-2.02), ABAX: 62.39 (+0.24), VASC: 28.66 (-0.69)
Credit Suisse: 8 Biotech and Health Care Stocks Add to Your Portfolio Right Now
at The Street - Thu Mar 05, 7:58AM CST
Biotechnology and health care in general are some of the hottest areas for investment these days.
PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), CAH: 87.01 (-1.94), CYH: 50.78 (-0.38), CS: 23.53 (-0.32), PTCT: 71.13 (-1.59), ILMN: 193.14 (-6.99), ABBV: 55.64 (-1.22), BMY: 65.12 (-0.93), AET: 100.67 (-1.42), CELG: 118.03 (-2.68)
Do-It-Yourself All Sector Dividend Aristocrat Portfolio
Aaron Barton - at Seeking Alpha - Wed Mar 04, 12:45PM CST
BDX: 144.88 (-4.62), MDT: 76.48 (-2.02), ED: 59.98 (-2.34), KMB: 106.82 (-1.64), SYY: 38.65 (-0.47), WMT: 82.59 (-0.98), HP: 67.18 (-0.94), GRC: 28.02 (-0.49), GWW: 235.27 (-2.77), UVV: 48.01 (+0.44), THFF: 33.58 (-0.31), T: 33.48 (-0.52), JNJ: 100.11 (-2.41), NWN: 45.03 (-1.22), EGN: 65.40 (-0.14), TGT: 77.21 (-0.99), CWT: 23.91 (-0.62), WEYS: 28.34 (-0.02), ORI: 14.88 (-0.09), NFG: 61.51 (-1.14), DBD: 34.28 (-0.86), KO: 41.52 (-0.88), STR: 22.80 (-0.47), ABT: 46.50 (-0.94), HCP: 40.34 (-1.60), ATO: 52.21 (-1.22), SCL: 39.65 (-1.08), MSEX: 21.67 (-0.45), ADP: 86.00 (-0.75), ADM: 46.25 (-1.23), MCD: 97.13 (-1.98), SJW: 31.59 (-0.69), DOV: 70.71 (-1.75), RAVN: 20.55 (-0.07), CVX: 103.55 (-1.18), NC: 54.25 (-1.86), AFL: 62.16 (-0.64), BRC: 26.31 (-0.31), ABM: 29.37 (-0.43)
Insider Trading Alert - DGAS, NMIH And MDT Traded By Insiders
at The Street - Tue Mar 03, 11:45AM CST
Stocks with insider trader activity include DGAS, NMIH and MDT
MDT: 76.48 (-2.02), NMIH: 7.32 (-0.08), DGAS: 19.74 (+0.08)
Court says no to Medtronic's $102M patent infringement award
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:38AM CST
MDT: 76.48 (-2.02), NUVA: 44.92 (-0.31)
Global POC Diagnostics Market 2015-2019 - High Prevalence of Diabetes and Obesity & Rapid Adoption of POC Diagnostic Tests
M2 - Tue Mar 03, 8:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/bngrb9/global_poc) has announced the addition of the "Global POC Diagnostics Market 2015-2019" report to their offering. The analysts forecast the Global POC Diagnostics market to grow at a CAGR of 8.47 percent over the period 2014-2019. POC diagnostics are IVD devices and tools used for diagnosing diseases in patients outside a clinical laboratory setting. The use of these devices helps in the rapid diagnosis of the medical conditions and aids in providing appropriate treatments and medication to patients. Rapid adoption of POC diagnostic tests is one of the key trends upcoming in this market. The use of POC diagnostics has been increasing over the past years as they provide rapid results and aid in immediate treatment decisions. This reduces the hospital stay of patients and delay in test results because of overcrowded emergency wards. According to the report, high prevalence of diabetes and obesity among patients worldwide is one major driver of the market. Unhealthy lifestyles and a lack of exercise result in a higher incidence of chronic diseases in people, which has increased the demand for POC diagnostics. Further, the report states that limitation of POC diagnostics is a major challenge that the market faces. The limited lifespan of the biomolecules and complications with quality control can restrict the use of POC diagnostics. To calculate the market size, the report considers revenue generated from the sales of POC diagnostics used in various applications: - Blood glucose testing - Infectious diseases testing - Cardiac markers testing - Coagulation testing - Pregnancy and fertility testing - Blood gas/electrolytes testing - Tumor markers testing - Urinalysis testing - Cholesterol testing Key Vendors - Abbott Laboratories - Alere - Bayer Healthcare - Danaher - F. Hoffmann-La Roche - Johnson & Johnson Other Prominent Vendors - A. Menarini Diagnostics - Abaxis - Acon - BD - Bio-Rad Laboratories - Chembio Diagnostics - Chongqing Haray International Business - Clarity Diagnostics - Clinical Innovations - Contec Medical - Eurotrol - Fudakang Ind'l - Helena Laboratories - i-sens - International Technidyne - Medtronic - Nipro Diagnostics - Nova Biomedical - OraSure Technologies - Phamatech - Quidel - Radiometer Medical - Randox Laboratories - SA Scientific - Sekisui Diagnostics - Shenzhen Fitconn Technology - Siemens Healthcare - STAT Technologies - Streck - TaiDoc For more information visit http://www.researchandmarkets.com/research/bngrb9/global_poc
JNJ: 100.11 (-2.41), ABT: 46.50 (-0.94), MDT: 76.48 (-2.02), ABAX: 62.39 (+0.24), DHR: 85.22 (-1.12), CEMI: 4.06 (+0.04), OSUR: 7.17 (+0.06)
Medtronic, Leading Neurostimulation Company, Invests in Flex Pharma IPO
Business Wire - Tue Mar 03, 7:30AM CST
(Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Medtronic invested in the Flex Pharma initial public offering on January 29, 2015.
MDT: 76.48 (-2.02), FLKS: 17.67 (-0.83)
NuVasive Announces Successful Appeal of Medtronic Verdict
Marketwired - Tue Mar 03, 7:02AM CST
NuVasive, Inc. (NASDAQ: NUVA) ("NuVasive" or the "Company"
, a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, today announced that the Court of Appeals for the Federal Circuit overturned the damages award in the Company's ongoing patent lawsuit with Medtronic Sofamor Danek USA, Inc. and Warsaw Orthopedic, Inc. ("Medtronic" .
MDT: 76.48 (-2.02), NUVA: 44.92 (-0.31)
HealthCare Sector in Focus: New Research on Arrhythmia, ZELTIQ, Medtronic, St. Jude Medical, and Varian Medical
PR Newswire - Tue Mar 03, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
ZLTQ: 31.24 (-0.52), HRT: 7.49 (+0.01), VAR: 93.18 (-1.04), MDT: 76.48 (-2.02), STJ: 66.53 (-1.20)
Post-Operative Pain - Pipeline Review, H1 2015 - 32 Companies & 42 Drug Profiles
M2 - Tue Mar 03, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/b9l5kz/postoperative) has announced the addition of the "Post-Operative Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Operative Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Operative Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - AngioChem Inc. - Boehringer Ingelheim GmbH - Cara Therapeutics, Inc. - Chong Kun Dang Pharmaceutical Corp. - Cytogel Pharma, LLC - DURECT Corporation - Echo Pharmaceuticals B.V. - Encore Therapeutics Inc. - Flexion Therapeutics, Inc. - Galleon Pharmaceuticals - Grunenthal GmbH - GW Pharmaceuticals plc - Heron Therapeutics, Inc. - Immupharma Plc - INSYS Therapeutics, Inc. - Laboratorios Del Dr. Esteve S.A. - Medtronic, Inc. - Ocular Therapeutix, Inc. - Omeros Corporation - Orbis Biosciences, Inc. - Orion Oyj - Pharmazz, Inc. - PhytoHealth Corporation - Recro Pharma, Inc. - Rottapharm SpA - Takeda Pharmaceutical Company Limited - Thar Pharmaceuticals, Inc. Drug Profiles - (bupivacaine hydrochloride meloxicam) - (dexketoprofen trometamol tramadol hydrochloride) - (ketoprofen amitriptyline oxymetazoline) - (ketorolac tromethamine phenylephrine hydrochloride) - AM-4 - ANG-2002 - ARX-01 - ARX-8028 - ARX-8203 - AYX-1 - BI-1026706 - bupivacaine hydrochloride - bupivacaine hydrochloride liposomal - bupivacaine hydrochloride SR - buprenorphine hydrochloride - centhaquine - CKD-943 - CMX-020 - CR-4056 - CR-845 - Cyt-1010 - dexamethasone acetate SR - dexmedetomidine hydrochloride - dronabinol - E-52862 - fadolmidine hydrochloride - FX-007 - GAL-044 - GIBH-1014 For more information visit http://www.researchandmarkets.com/research/b9...toperative
ACRX: 8.74 (-0.27), INSY: 57.69 (+0.08), FLXN: 24.11 (-1.16), MDT: 76.48 (-2.02), HRTX: 14.58 (-0.89), DRRX: 1.64 (+0.30), REPH: 3.29 (unch), OMER: 26.14 (-0.21), OCUL: 39.60 (-0.16)
Global Patient Temperature Management Market 2015-2019 - Increase in Number of Surgical Procedures because of Aging Population
M2 - Tue Mar 03, 5:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/b8vzqn/global_patient) has announced the addition of the "Global Patient Temperature Management Market 2015-2019" report to their offering. The Global Patient Temperature Management market to grow at a CAGR of 7.74% over the period 2014-2019 This report covers the present scenario and the growth prospects of the Global Patient Temperature Management market for the period 2015-2019. The market can be segmented into two: Warming Devices and Cooling Devices. Approximately 16.40% of the world's population is above 65 years. This percentage is expected to increase to 18.70% by 2020. The elderly are more susceptible to traumatic injuries, arthritis, soft tissue inflammation, cardiac problems, obesity-related problems, and other chronic diseases. This, in turn, increases the demand for age-related surgeries. Since patients under anesthesia cannot regulate their body temperature, they are at risk for inadvertent hypothermia-related complications. According to the report, The launch of a new product from the R&D stage to commercialization is a very expensive process. Vendors make huge investments in R&D to gain market shares. Rapid developments in technology may result in the success or failure of a product during the R&D process. In addition, the long R&D and approval process may result in product obsolescence. Further, Leading vendors are opting for M&A to strengthen their global position and to increase their commercial capabilities. For instance, to achieve high economies of scale, Covidien and Medtronics entered into a partnership for US$42.90 billion in June 2014, ZOLL Medical acquired Philips InnerCool Temperature Management in November 2014, C.R. Bard acquired Medivance in 2011, Stryker acquired Gaymar Industries, and 3M Healthcare acquired Arizant Healthcare in 2010. These acquisitions result in wide product portfolios and, thus, have a positive effect on the growth of the market. Market Drivers/Challenge/Trend - Increase in Number of Surgical Procedures because of Aging Population - High R&D Expenses - Increase in M&A Key Vendors - 3M Healthcare - C. R. Bard - Smiths Medical - Stryker - ZOLL Medical Other Prominent Vendors - Augustine Temperature Management - Belmont Instrument - Charter Kontron - Cincinnati Sub-Zero (CSZ) Products - Ecolab - EMIT - Enthermics Medical Systems - GE Healthcare - Geratherm Medical - Healthcare 21 - Inditherm - Medtronic (Medtronic acquired Covidien) - Mennen Medical Group - Moeck und Moeck - Pintler Medical - The 37Company - Welkins For more information visit http://www.researchandmarkets.com/research/b8...al_patient
MDT: 76.48 (-2.02), MDSY: 2.30 (-0.09), ECL: 114.69 (-2.08)
Tracking The Hotchkis & Wiley Value Opportunities Fund: Q4 2014 Update
V is for Value - at Seeking Alpha - Mon Mar 02, 9:40PM CST
SPLS: 16.05 (-0.45), CNW: 44.34 (+0.27), DOOR: 62.29 (-0.20), KOS: 8.28 (+0.01), GXP: 25.80 (-0.53), ESRX: 82.27 (-2.01), JPM: 60.89 (-1.11), NOR: 2.96 (unch), KBR: 15.49 (-0.32), HMC: 33.52 (+0.28), MSFT: 42.36 (-0.75), COV: 106.71 (-1.36), LACO: 8.65 (+0.24), HSON: 2.82 (-0.02), GSK: 46.73 (-0.87), SAH: 23.52 (-0.50), DRIV: 25.99 (+0.06), RDS.B: 64.48 (-1.14), GEO: 41.50 (-2.44), KALU: 75.09 (-0.32), AIG: 56.00 (+0.39), CPN: 20.60 (-0.38), MDT: 76.48 (-2.02), C: 53.06 (-0.50), AIRT: 19.63 (unch), CIE: 9.91 (-0.03), IBM: 158.50 (-2.68), SNY: 47.42 (-0.94), GBLI: 26.55 (-0.18), DRC: 81.25 (-0.03), BAC: 16.22 (+0.22), GLW: 24.03 (-0.59), HPQ: 33.18 (-0.82), ORCL: 42.38 (-1.42), HELE: 75.81 (-0.99), RCII: 27.35 (+0.24), GM: 36.84 (-0.77), MTOR: 13.70 (-0.10), MLR: 20.89 (-0.12), HGR: 25.43 (-0.52), RDC: 19.85 (-0.67)
3 Best Performing Stocks in February - Analyst Blog
Swarup Gupta - Zacks Investment Research - Mon Mar 02, 9:42AM CST
Markets experienced their best month in more than two years in February, right after a particularly tough January.
SPLS: 16.05 (-0.45), KO: 41.52 (-0.88), VRX: 198.71 (-5.24), MDT: 76.48 (-2.02), PFE: 33.97 (-0.50), SLXP: 158.01 (+0.57), DIS: 103.82 (-1.21), HRL: 56.76 (-1.18), BMY: 65.12 (-0.93), HSP: 87.90 (+0.05), PEP: 96.17 (-1.06), GM: 36.84 (-0.77), ODP: 9.30 (-0.04), EL: 82.23 (-0.99), CSCO: 28.92 (-0.38), ONNN: 12.90 (-0.14)
Global Transcatheter Aortic Valve Replacement (TAVR) Market Report: 2015 Edition
M2 - Mon Mar 02, 8:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/rkdcc5/global) has announced the addition of the "Global Transcatheter Aortic Valve Replacement (TAVR) Market Report: 2015 Edition" report to their offering. Transcatheter aortic valve replacement (TAVR) is a relatively new technology in the field of medical science. It is a minimally invasive procedure to replace a narrowed aortic valve that fails to open properly (aortic stenosis). It is sometimes also called transcatheter aortic valve implantation (TAVI). Aortic valve replacement typically requires open heart surgery, thus it disqualifies patients who are at high risk for the process or are too weak to undergo a surgery. As a result, the market of heart valve surgical procedures is witnessing a continuous decline as more and more patients requiring valve replacement are at risk for a surgical treatment. This shortcoming of the traditional surgical method has paved way for the popularity and adoption of TAVR. It was first commercially launched in Europe in 2007 and later in the United States. The market for TAVR is regarded to be promising with immense growth opportunities and unmet demand to cater to. The key factors which are anticipated to drive market growth include ageing population, healthcare expenditure, increasing obese population and gross domestic product apart from increasing prevalence of inoperable aortic stenosis. Some of the noteworthy developments of this industry include advancement in technologies and favorable reimbursement in Europe. However, the industry remains threatened by certain challenges which include regulatory issues, associated high risk and high cost of TAVR devices. This report offers a comprehensive analysis of the global TAVR market, along with an in-depth study of the TAVR procedures and the regional markets of the US, Europe and Japan. The global TAVR market is dominated by two major players, Edwards Lifesciences and Medtronic which operate in a highly dynamic environment working in the direction of tapping maximum market share. Both the companies in addition to St. Jude Medical have been profiled in the present report highlighting their key financials and business strategies for growth. Key Topics Covered: 1. Market Overview 2. TAVR Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Edwards Lifesciences - Medtronic - St. Jude Medical For more information visit http://www.researchandmarkets.com/research/rkdcc5/global
MDT: 76.48 (-2.02), STJ: 66.53 (-1.20), EW: 133.00 (-2.65)
Freedom Fund Update - March 2015
Dividend Mantra - Seeking Alpha - Mon Mar 02, 5:35AM CST
Well, the time has come to update the Freedom Fund once again as we start another month. The Freedom Fund is my portfolio, and I think it's aptly named. My portfolio is my way to freedom; freedom from a job I don't desire, to purchase goods I don't...
NOV: 52.54 (-1.06), MDT: 76.48 (-2.02), OHI: 38.02 (-1.99), O: 48.73 (-2.07)
Regulatory Compliance Associates(R) Inc. Welcomes Seyed Khorashahi as Chief Operating Officer
PRWeb - Mon Mar 02, 2:06AM CST
Regulatory Compliance Associates(R) Inc. (RCA), a life sciences consultancy focused on quality, regulatory and technical consulting, announces Mr. Seyed Khorashahi has accepted a role as Chief Operating Officer.
MDT: 76.48 (-2.02)
Some Companies Are More Wonderful Than Others
Investing Doc - at Seeking Alpha - Sun Mar 01, 4:02AM CST
BBT: 38.46 (+0.49), MON: 118.17 (-1.10), EA: 56.36 (-1.02), HSY: 99.65 (-2.70), ED: 59.98 (-2.34), SYY: 38.65 (-0.47), LM: 56.65 (-0.60), INTC: 33.19 (-0.54), UPS: 100.62 (-0.10), PGR: 26.26 (-0.28), BSX: 16.56 (-0.41), SPY: 207.50 (-2.96), JPM: 60.89 (-1.11), COF: 78.98 (+0.09), FII: 34.35 (+0.55), DE: 90.26 (-0.20), LOW: 73.51 (-1.05), MSFT: 42.36 (-0.75), ROK: 112.36 (-1.84), CSCO: 28.92 (-0.38), MA: 90.79 (-2.02), SYK: 90.07 (-2.92), BCS: 15.84 (-0.33), BCR: 166.67 (-3.61), ISCA: 31.33 (-0.35), RNR: 101.05 (-0.18), PFE: 33.97 (-0.50), WFC: 54.59 (-0.25), MO: 53.37 (-2.13), ISRG: 494.04 (-5.48), CPB: 45.10 (-1.18), SHW: 286.44 (-2.73), CVX: 103.55 (-1.18), INTU: 97.41 (-0.71), ADSK: 61.74 (-1.21), NVS: 97.46 (-1.49), GD: 134.60 (-1.83), MMM: 164.36 (-3.21), BDX: 144.88 (-4.62), GE: 25.42 (-0.40), CHRW: 73.58 (-0.54), CLX: 108.69 (-1.47), MDT: 76.48 (-2.02), BLK: 365.47 (-4.47), KMB: 106.82 (-1.64), C: 53.06 (-0.50), KEY: 14.31 (+0.23), MMC: 56.35 (-0.64), JNJ: 100.11 (-2.41), CME: 95.42 (-1.40), CINF: 52.47 (-0.28), PPG: 231.97 (-3.48), BMO: 60.40 (-0.63), FITB: 19.45 (+0.14), HD: 114.45 (-1.46), WU: 19.45 (-0.04), GGG: 74.22 (-1.18), EMR: 56.56 (-1.52), BMY: 65.12 (-0.93), CTAS: 82.28 (-0.66), JOE: 16.47 (-0.28), USB: 44.67 (+0.09), PG: 82.66 (-1.97), IGT: 17.86 (-0.01), BEN: 53.05 (-1.02), CMCSA: 60.37 (+0.04), MXIM: 35.67 (+0.06), RF: 9.76 (+0.06), MKC: 73.45 (-1.28), UTX: 119.43 (-1.36), MTB: 124.43 (+1.21), WMT: 82.59 (-0.98), GOOG: 567.68 (-7.65), SLB: 83.11 (-1.71), SLM: 9.48 (-0.03), TGT: 77.21 (-0.99), LYG: 4.88 (-0.08), FWRD: 52.91 (-0.21), CLMS: 12.42 (-0.27), STR: 22.80 (-0.47), AVP: 8.90 (-0.15), STT: 72.81 (-1.86), VFC: 74.49 (-1.58), LLTC: 47.65 (-0.72), IRM: 36.28 (-0.31), MHFI: 101.43 (-1.37), FDO: 78.80 (+0.10), GSK: 46.73 (-0.87), TIF: 85.17 (-1.81), ADP: 86.00 (-0.75), WBA: 82.35 (-0.85), SIAL: 138.08 (+0.03), MRK: 56.84 (-1.14), EXPD: 47.66 (-0.31), MCD: 97.13 (-1.98), DOV: 70.71 (-1.75), BRK.B: 145.28 (-0.78), WTW: 9.47 (-0.08), CTL: 35.42 (-0.71), BIIB: 417.63 (-7.98), LMT: 197.66 (-1.44), XOM: 85.63 (-1.11), PEP: 96.17 (-1.06), TWX: 84.12 (+0.86), SWK: 95.68 (-1.94), SBUX: 92.21 (-1.42), PAYX: 48.95 (-0.23), FAST: 40.55 (-0.07), EBAY: 59.87 (+0.79), QCOM: 71.50 (+0.57), DIA: 178.40 (-2.77), SNV: 28.00 (+0.34), AVY: 52.25 (-0.75), SNY: 47.42 (-0.94), BK: 39.28 (+0.09), HRB: 32.12 (+0.11), KO: 41.52 (-0.88), AXP: 80.31 (-0.84), SVU: 10.24 (-0.17), NUE: 47.03 (-0.61), LEG: 44.93 (-0.81), AMGN: 154.88 (-4.72), DIS: 103.82 (-1.21), BAC: 16.22 (+0.22), ORCL: 42.38 (-1.42), BRO: 31.84 (-0.02), JCI: 49.86 (-0.72), CL: 69.25 (-2.21)
Seeking Alpha's Biotech Weekly: Achillion Overdone, Sanofi's Toujeo A Go, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CYTK: 7.80 (-0.11), VRX: 198.71 (-5.24), ACT: 289.92 (-5.78), PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), CAH: 87.01 (-1.94), CLDX: 29.39 (-0.39), HSP: 87.90 (+0.05), AGN: 233.51 (-1.90), JNJ: 100.11 (-2.41), ATOS: 1.97 (-0.04), ONVO: 5.59 (-0.13), PTCT: 71.13 (-1.59), SNY: 47.42 (-0.94), PTLA: 41.72 (-0.13), INCY: 90.00 (-1.97), PFE: 33.97 (-0.50), CPHR: 11.67 (-0.33), MYL: 55.44 (-1.25), AMGN: 154.88 (-4.72), LLY: 68.41 (-2.18), BMY: 65.12 (-0.93), MNKD: 5.47 (-0.26), NKTR: 13.02 (-0.28), OMER: 26.14 (-0.21), DVA: 77.63 (+0.70), GILD: 101.81 (-1.61), SGEN: 35.32 (-0.28), ACHN: 11.39 (+0.40), MRK: 56.84 (-1.14), TEVA: 56.40 (-0.11), BIL: 45.72 (-0.01), ARIA: 8.08 (-0.17), NVS: 97.46 (-1.49)
Seeking Alpha's Biotech Weekly: AbbVie - Pharmacyclitics, Orexigen Confusion, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), ARWR: 7.75 (-0.19), SPHS: 0.70 (-0.03), BSX: 16.56 (-0.41), MDVN: 126.55 (-0.53), JNJ: 100.11 (-2.41), AAC: 29.30 (-2.80), ABBV: 55.64 (-1.22), SNY: 47.42 (-0.94), SMMT: 10.29 (+0.10), ARNA: 4.32 (+0.09), XLRN: 40.55 (-0.79), MNK: 121.33 (-0.37), AQXP: 10.49 (+0.43), PFE: 33.97 (-0.50), AMGN: 154.88 (-4.72), GSK: 46.73 (-0.87), BMY: 65.12 (-0.93), MNKD: 5.47 (-0.26), CELG: 118.03 (-2.68), OREX: 7.10 (-0.91), PODD: 32.24 (+0.26), GERN: 3.50 (-0.28), TEVA: 56.40 (-0.11), TCON: 17.57 (+0.36), NVS: 97.46 (-1.49)
Stock Market News for March 06, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 9:10AM CST
Markets snapped a two-day losing streak on Thursday, somewhat boosted by the ECB announcing a trillion-dollar stimulus plan that will kick off on Monday
BIIB: 417.63 (-7.98), JNJ: 100.11 (-2.41), PCYC: 254.56 (+0.34), ADP: 86.00 (-0.75), MDT: 76.48 (-2.02), GILD: 101.81 (-1.61), ABBV: 55.64 (-1.22), BMY: 65.12 (-0.93)
Medtronic Positive on Covidien Integration, Potential Synergy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 05, 1:30PM CST
On Mar 4, 2015, we issued an updated research report on Medtronic, Inc. (MDT).
CSII: 36.10 (-1.36), MDT: 76.48 (-2.02), ABAX: 62.39 (+0.24), VASC: 28.66 (-0.69)
Credit Suisse: 8 Biotech and Health Care Stocks Add to Your Portfolio Right Now
at The Street - Thu Mar 05, 7:58AM CST
Biotechnology and health care in general are some of the hottest areas for investment these days.
PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), CAH: 87.01 (-1.94), CYH: 50.78 (-0.38), CS: 23.53 (-0.32), PTCT: 71.13 (-1.59), ILMN: 193.14 (-6.99), ABBV: 55.64 (-1.22), BMY: 65.12 (-0.93), AET: 100.67 (-1.42), CELG: 118.03 (-2.68)
Do-It-Yourself All Sector Dividend Aristocrat Portfolio
Aaron Barton - at Seeking Alpha - Wed Mar 04, 12:45PM CST
BDX: 144.88 (-4.62), MDT: 76.48 (-2.02), ED: 59.98 (-2.34), KMB: 106.82 (-1.64), SYY: 38.65 (-0.47), WMT: 82.59 (-0.98), HP: 67.18 (-0.94), GRC: 28.02 (-0.49), GWW: 235.27 (-2.77), UVV: 48.01 (+0.44), THFF: 33.58 (-0.31), T: 33.48 (-0.52), JNJ: 100.11 (-2.41), NWN: 45.03 (-1.22), EGN: 65.40 (-0.14), TGT: 77.21 (-0.99), CWT: 23.91 (-0.62), WEYS: 28.34 (-0.02), ORI: 14.88 (-0.09), NFG: 61.51 (-1.14), DBD: 34.28 (-0.86), KO: 41.52 (-0.88), STR: 22.80 (-0.47), ABT: 46.50 (-0.94), HCP: 40.34 (-1.60), ATO: 52.21 (-1.22), SCL: 39.65 (-1.08), MSEX: 21.67 (-0.45), ADP: 86.00 (-0.75), ADM: 46.25 (-1.23), MCD: 97.13 (-1.98), SJW: 31.59 (-0.69), DOV: 70.71 (-1.75), RAVN: 20.55 (-0.07), CVX: 103.55 (-1.18), NC: 54.25 (-1.86), AFL: 62.16 (-0.64), BRC: 26.31 (-0.31), ABM: 29.37 (-0.43)
Insider Trading Alert - DGAS, NMIH And MDT Traded By Insiders
at The Street - Tue Mar 03, 11:45AM CST
Stocks with insider trader activity include DGAS, NMIH and MDT
MDT: 76.48 (-2.02), NMIH: 7.32 (-0.08), DGAS: 19.74 (+0.08)
Court says no to Medtronic's $102M patent infringement award
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:38AM CST
MDT: 76.48 (-2.02), NUVA: 44.92 (-0.31)
Global POC Diagnostics Market 2015-2019 - High Prevalence of Diabetes and Obesity & Rapid Adoption of POC Diagnostic Tests
M2 - Tue Mar 03, 8:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/bngrb9/global_poc) has announced the addition of the "Global POC Diagnostics Market 2015-2019" report to their offering. The analysts forecast the Global POC Diagnostics market to grow at a CAGR of 8.47 percent over the period 2014-2019. POC diagnostics are IVD devices and tools used for diagnosing diseases in patients outside a clinical laboratory setting. The use of these devices helps in the rapid diagnosis of the medical conditions and aids in providing appropriate treatments and medication to patients. Rapid adoption of POC diagnostic tests is one of the key trends upcoming in this market. The use of POC diagnostics has been increasing over the past years as they provide rapid results and aid in immediate treatment decisions. This reduces the hospital stay of patients and delay in test results because of overcrowded emergency wards. According to the report, high prevalence of diabetes and obesity among patients worldwide is one major driver of the market. Unhealthy lifestyles and a lack of exercise result in a higher incidence of chronic diseases in people, which has increased the demand for POC diagnostics. Further, the report states that limitation of POC diagnostics is a major challenge that the market faces. The limited lifespan of the biomolecules and complications with quality control can restrict the use of POC diagnostics. To calculate the market size, the report considers revenue generated from the sales of POC diagnostics used in various applications: - Blood glucose testing - Infectious diseases testing - Cardiac markers testing - Coagulation testing - Pregnancy and fertility testing - Blood gas/electrolytes testing - Tumor markers testing - Urinalysis testing - Cholesterol testing Key Vendors - Abbott Laboratories - Alere - Bayer Healthcare - Danaher - F. Hoffmann-La Roche - Johnson & Johnson Other Prominent Vendors - A. Menarini Diagnostics - Abaxis - Acon - BD - Bio-Rad Laboratories - Chembio Diagnostics - Chongqing Haray International Business - Clarity Diagnostics - Clinical Innovations - Contec Medical - Eurotrol - Fudakang Ind'l - Helena Laboratories - i-sens - International Technidyne - Medtronic - Nipro Diagnostics - Nova Biomedical - OraSure Technologies - Phamatech - Quidel - Radiometer Medical - Randox Laboratories - SA Scientific - Sekisui Diagnostics - Shenzhen Fitconn Technology - Siemens Healthcare - STAT Technologies - Streck - TaiDoc For more information visit http://www.researchandmarkets.com/research/bngrb9/global_poc
JNJ: 100.11 (-2.41), ABT: 46.50 (-0.94), MDT: 76.48 (-2.02), ABAX: 62.39 (+0.24), DHR: 85.22 (-1.12), CEMI: 4.06 (+0.04), OSUR: 7.17 (+0.06)
Medtronic, Leading Neurostimulation Company, Invests in Flex Pharma IPO
Business Wire - Tue Mar 03, 7:30AM CST
(Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Medtronic invested in the Flex Pharma initial public offering on January 29, 2015.
MDT: 76.48 (-2.02), FLKS: 17.67 (-0.83)
NuVasive Announces Successful Appeal of Medtronic Verdict
Marketwired - Tue Mar 03, 7:02AM CST
NuVasive, Inc. (NASDAQ: NUVA) ("NuVasive" or the "Company"
, a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, today announced that the Court of Appeals for the Federal Circuit overturned the damages award in the Company's ongoing patent lawsuit with Medtronic Sofamor Danek USA, Inc. and Warsaw Orthopedic, Inc. ("Medtronic" . MDT: 76.48 (-2.02), NUVA: 44.92 (-0.31)
HealthCare Sector in Focus: New Research on Arrhythmia, ZELTIQ, Medtronic, St. Jude Medical, and Varian Medical
PR Newswire - Tue Mar 03, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
ZLTQ: 31.24 (-0.52), HRT: 7.49 (+0.01), VAR: 93.18 (-1.04), MDT: 76.48 (-2.02), STJ: 66.53 (-1.20)
Post-Operative Pain - Pipeline Review, H1 2015 - 32 Companies & 42 Drug Profiles
M2 - Tue Mar 03, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/b9l5kz/postoperative) has announced the addition of the "Post-Operative Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Operative Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Operative Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - AngioChem Inc. - Boehringer Ingelheim GmbH - Cara Therapeutics, Inc. - Chong Kun Dang Pharmaceutical Corp. - Cytogel Pharma, LLC - DURECT Corporation - Echo Pharmaceuticals B.V. - Encore Therapeutics Inc. - Flexion Therapeutics, Inc. - Galleon Pharmaceuticals - Grunenthal GmbH - GW Pharmaceuticals plc - Heron Therapeutics, Inc. - Immupharma Plc - INSYS Therapeutics, Inc. - Laboratorios Del Dr. Esteve S.A. - Medtronic, Inc. - Ocular Therapeutix, Inc. - Omeros Corporation - Orbis Biosciences, Inc. - Orion Oyj - Pharmazz, Inc. - PhytoHealth Corporation - Recro Pharma, Inc. - Rottapharm SpA - Takeda Pharmaceutical Company Limited - Thar Pharmaceuticals, Inc. Drug Profiles - (bupivacaine hydrochloride meloxicam) - (dexketoprofen trometamol tramadol hydrochloride) - (ketoprofen amitriptyline oxymetazoline) - (ketorolac tromethamine phenylephrine hydrochloride) - AM-4 - ANG-2002 - ARX-01 - ARX-8028 - ARX-8203 - AYX-1 - BI-1026706 - bupivacaine hydrochloride - bupivacaine hydrochloride liposomal - bupivacaine hydrochloride SR - buprenorphine hydrochloride - centhaquine - CKD-943 - CMX-020 - CR-4056 - CR-845 - Cyt-1010 - dexamethasone acetate SR - dexmedetomidine hydrochloride - dronabinol - E-52862 - fadolmidine hydrochloride - FX-007 - GAL-044 - GIBH-1014 For more information visit http://www.researchandmarkets.com/research/b9...toperative
ACRX: 8.74 (-0.27), INSY: 57.69 (+0.08), FLXN: 24.11 (-1.16), MDT: 76.48 (-2.02), HRTX: 14.58 (-0.89), DRRX: 1.64 (+0.30), REPH: 3.29 (unch), OMER: 26.14 (-0.21), OCUL: 39.60 (-0.16)
Global Patient Temperature Management Market 2015-2019 - Increase in Number of Surgical Procedures because of Aging Population
M2 - Tue Mar 03, 5:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/b8vzqn/global_patient) has announced the addition of the "Global Patient Temperature Management Market 2015-2019" report to their offering. The Global Patient Temperature Management market to grow at a CAGR of 7.74% over the period 2014-2019 This report covers the present scenario and the growth prospects of the Global Patient Temperature Management market for the period 2015-2019. The market can be segmented into two: Warming Devices and Cooling Devices. Approximately 16.40% of the world's population is above 65 years. This percentage is expected to increase to 18.70% by 2020. The elderly are more susceptible to traumatic injuries, arthritis, soft tissue inflammation, cardiac problems, obesity-related problems, and other chronic diseases. This, in turn, increases the demand for age-related surgeries. Since patients under anesthesia cannot regulate their body temperature, they are at risk for inadvertent hypothermia-related complications. According to the report, The launch of a new product from the R&D stage to commercialization is a very expensive process. Vendors make huge investments in R&D to gain market shares. Rapid developments in technology may result in the success or failure of a product during the R&D process. In addition, the long R&D and approval process may result in product obsolescence. Further, Leading vendors are opting for M&A to strengthen their global position and to increase their commercial capabilities. For instance, to achieve high economies of scale, Covidien and Medtronics entered into a partnership for US$42.90 billion in June 2014, ZOLL Medical acquired Philips InnerCool Temperature Management in November 2014, C.R. Bard acquired Medivance in 2011, Stryker acquired Gaymar Industries, and 3M Healthcare acquired Arizant Healthcare in 2010. These acquisitions result in wide product portfolios and, thus, have a positive effect on the growth of the market. Market Drivers/Challenge/Trend - Increase in Number of Surgical Procedures because of Aging Population - High R&D Expenses - Increase in M&A Key Vendors - 3M Healthcare - C. R. Bard - Smiths Medical - Stryker - ZOLL Medical Other Prominent Vendors - Augustine Temperature Management - Belmont Instrument - Charter Kontron - Cincinnati Sub-Zero (CSZ) Products - Ecolab - EMIT - Enthermics Medical Systems - GE Healthcare - Geratherm Medical - Healthcare 21 - Inditherm - Medtronic (Medtronic acquired Covidien) - Mennen Medical Group - Moeck und Moeck - Pintler Medical - The 37Company - Welkins For more information visit http://www.researchandmarkets.com/research/b8...al_patient
MDT: 76.48 (-2.02), MDSY: 2.30 (-0.09), ECL: 114.69 (-2.08)
Tracking The Hotchkis & Wiley Value Opportunities Fund: Q4 2014 Update
V is for Value - at Seeking Alpha - Mon Mar 02, 9:40PM CST
SPLS: 16.05 (-0.45), CNW: 44.34 (+0.27), DOOR: 62.29 (-0.20), KOS: 8.28 (+0.01), GXP: 25.80 (-0.53), ESRX: 82.27 (-2.01), JPM: 60.89 (-1.11), NOR: 2.96 (unch), KBR: 15.49 (-0.32), HMC: 33.52 (+0.28), MSFT: 42.36 (-0.75), COV: 106.71 (-1.36), LACO: 8.65 (+0.24), HSON: 2.82 (-0.02), GSK: 46.73 (-0.87), SAH: 23.52 (-0.50), DRIV: 25.99 (+0.06), RDS.B: 64.48 (-1.14), GEO: 41.50 (-2.44), KALU: 75.09 (-0.32), AIG: 56.00 (+0.39), CPN: 20.60 (-0.38), MDT: 76.48 (-2.02), C: 53.06 (-0.50), AIRT: 19.63 (unch), CIE: 9.91 (-0.03), IBM: 158.50 (-2.68), SNY: 47.42 (-0.94), GBLI: 26.55 (-0.18), DRC: 81.25 (-0.03), BAC: 16.22 (+0.22), GLW: 24.03 (-0.59), HPQ: 33.18 (-0.82), ORCL: 42.38 (-1.42), HELE: 75.81 (-0.99), RCII: 27.35 (+0.24), GM: 36.84 (-0.77), MTOR: 13.70 (-0.10), MLR: 20.89 (-0.12), HGR: 25.43 (-0.52), RDC: 19.85 (-0.67)
3 Best Performing Stocks in February - Analyst Blog
Swarup Gupta - Zacks Investment Research - Mon Mar 02, 9:42AM CST
Markets experienced their best month in more than two years in February, right after a particularly tough January.
SPLS: 16.05 (-0.45), KO: 41.52 (-0.88), VRX: 198.71 (-5.24), MDT: 76.48 (-2.02), PFE: 33.97 (-0.50), SLXP: 158.01 (+0.57), DIS: 103.82 (-1.21), HRL: 56.76 (-1.18), BMY: 65.12 (-0.93), HSP: 87.90 (+0.05), PEP: 96.17 (-1.06), GM: 36.84 (-0.77), ODP: 9.30 (-0.04), EL: 82.23 (-0.99), CSCO: 28.92 (-0.38), ONNN: 12.90 (-0.14)
Global Transcatheter Aortic Valve Replacement (TAVR) Market Report: 2015 Edition
M2 - Mon Mar 02, 8:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/rkdcc5/global) has announced the addition of the "Global Transcatheter Aortic Valve Replacement (TAVR) Market Report: 2015 Edition" report to their offering. Transcatheter aortic valve replacement (TAVR) is a relatively new technology in the field of medical science. It is a minimally invasive procedure to replace a narrowed aortic valve that fails to open properly (aortic stenosis). It is sometimes also called transcatheter aortic valve implantation (TAVI). Aortic valve replacement typically requires open heart surgery, thus it disqualifies patients who are at high risk for the process or are too weak to undergo a surgery. As a result, the market of heart valve surgical procedures is witnessing a continuous decline as more and more patients requiring valve replacement are at risk for a surgical treatment. This shortcoming of the traditional surgical method has paved way for the popularity and adoption of TAVR. It was first commercially launched in Europe in 2007 and later in the United States. The market for TAVR is regarded to be promising with immense growth opportunities and unmet demand to cater to. The key factors which are anticipated to drive market growth include ageing population, healthcare expenditure, increasing obese population and gross domestic product apart from increasing prevalence of inoperable aortic stenosis. Some of the noteworthy developments of this industry include advancement in technologies and favorable reimbursement in Europe. However, the industry remains threatened by certain challenges which include regulatory issues, associated high risk and high cost of TAVR devices. This report offers a comprehensive analysis of the global TAVR market, along with an in-depth study of the TAVR procedures and the regional markets of the US, Europe and Japan. The global TAVR market is dominated by two major players, Edwards Lifesciences and Medtronic which operate in a highly dynamic environment working in the direction of tapping maximum market share. Both the companies in addition to St. Jude Medical have been profiled in the present report highlighting their key financials and business strategies for growth. Key Topics Covered: 1. Market Overview 2. TAVR Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Edwards Lifesciences - Medtronic - St. Jude Medical For more information visit http://www.researchandmarkets.com/research/rkdcc5/global
MDT: 76.48 (-2.02), STJ: 66.53 (-1.20), EW: 133.00 (-2.65)
Freedom Fund Update - March 2015
Dividend Mantra - Seeking Alpha - Mon Mar 02, 5:35AM CST
Well, the time has come to update the Freedom Fund once again as we start another month. The Freedom Fund is my portfolio, and I think it's aptly named. My portfolio is my way to freedom; freedom from a job I don't desire, to purchase goods I don't...
NOV: 52.54 (-1.06), MDT: 76.48 (-2.02), OHI: 38.02 (-1.99), O: 48.73 (-2.07)
Regulatory Compliance Associates(R) Inc. Welcomes Seyed Khorashahi as Chief Operating Officer
PRWeb - Mon Mar 02, 2:06AM CST
Regulatory Compliance Associates(R) Inc. (RCA), a life sciences consultancy focused on quality, regulatory and technical consulting, announces Mr. Seyed Khorashahi has accepted a role as Chief Operating Officer.
MDT: 76.48 (-2.02)
Some Companies Are More Wonderful Than Others
Investing Doc - at Seeking Alpha - Sun Mar 01, 4:02AM CST
BBT: 38.46 (+0.49), MON: 118.17 (-1.10), EA: 56.36 (-1.02), HSY: 99.65 (-2.70), ED: 59.98 (-2.34), SYY: 38.65 (-0.47), LM: 56.65 (-0.60), INTC: 33.19 (-0.54), UPS: 100.62 (-0.10), PGR: 26.26 (-0.28), BSX: 16.56 (-0.41), SPY: 207.50 (-2.96), JPM: 60.89 (-1.11), COF: 78.98 (+0.09), FII: 34.35 (+0.55), DE: 90.26 (-0.20), LOW: 73.51 (-1.05), MSFT: 42.36 (-0.75), ROK: 112.36 (-1.84), CSCO: 28.92 (-0.38), MA: 90.79 (-2.02), SYK: 90.07 (-2.92), BCS: 15.84 (-0.33), BCR: 166.67 (-3.61), ISCA: 31.33 (-0.35), RNR: 101.05 (-0.18), PFE: 33.97 (-0.50), WFC: 54.59 (-0.25), MO: 53.37 (-2.13), ISRG: 494.04 (-5.48), CPB: 45.10 (-1.18), SHW: 286.44 (-2.73), CVX: 103.55 (-1.18), INTU: 97.41 (-0.71), ADSK: 61.74 (-1.21), NVS: 97.46 (-1.49), GD: 134.60 (-1.83), MMM: 164.36 (-3.21), BDX: 144.88 (-4.62), GE: 25.42 (-0.40), CHRW: 73.58 (-0.54), CLX: 108.69 (-1.47), MDT: 76.48 (-2.02), BLK: 365.47 (-4.47), KMB: 106.82 (-1.64), C: 53.06 (-0.50), KEY: 14.31 (+0.23), MMC: 56.35 (-0.64), JNJ: 100.11 (-2.41), CME: 95.42 (-1.40), CINF: 52.47 (-0.28), PPG: 231.97 (-3.48), BMO: 60.40 (-0.63), FITB: 19.45 (+0.14), HD: 114.45 (-1.46), WU: 19.45 (-0.04), GGG: 74.22 (-1.18), EMR: 56.56 (-1.52), BMY: 65.12 (-0.93), CTAS: 82.28 (-0.66), JOE: 16.47 (-0.28), USB: 44.67 (+0.09), PG: 82.66 (-1.97), IGT: 17.86 (-0.01), BEN: 53.05 (-1.02), CMCSA: 60.37 (+0.04), MXIM: 35.67 (+0.06), RF: 9.76 (+0.06), MKC: 73.45 (-1.28), UTX: 119.43 (-1.36), MTB: 124.43 (+1.21), WMT: 82.59 (-0.98), GOOG: 567.68 (-7.65), SLB: 83.11 (-1.71), SLM: 9.48 (-0.03), TGT: 77.21 (-0.99), LYG: 4.88 (-0.08), FWRD: 52.91 (-0.21), CLMS: 12.42 (-0.27), STR: 22.80 (-0.47), AVP: 8.90 (-0.15), STT: 72.81 (-1.86), VFC: 74.49 (-1.58), LLTC: 47.65 (-0.72), IRM: 36.28 (-0.31), MHFI: 101.43 (-1.37), FDO: 78.80 (+0.10), GSK: 46.73 (-0.87), TIF: 85.17 (-1.81), ADP: 86.00 (-0.75), WBA: 82.35 (-0.85), SIAL: 138.08 (+0.03), MRK: 56.84 (-1.14), EXPD: 47.66 (-0.31), MCD: 97.13 (-1.98), DOV: 70.71 (-1.75), BRK.B: 145.28 (-0.78), WTW: 9.47 (-0.08), CTL: 35.42 (-0.71), BIIB: 417.63 (-7.98), LMT: 197.66 (-1.44), XOM: 85.63 (-1.11), PEP: 96.17 (-1.06), TWX: 84.12 (+0.86), SWK: 95.68 (-1.94), SBUX: 92.21 (-1.42), PAYX: 48.95 (-0.23), FAST: 40.55 (-0.07), EBAY: 59.87 (+0.79), QCOM: 71.50 (+0.57), DIA: 178.40 (-2.77), SNV: 28.00 (+0.34), AVY: 52.25 (-0.75), SNY: 47.42 (-0.94), BK: 39.28 (+0.09), HRB: 32.12 (+0.11), KO: 41.52 (-0.88), AXP: 80.31 (-0.84), SVU: 10.24 (-0.17), NUE: 47.03 (-0.61), LEG: 44.93 (-0.81), AMGN: 154.88 (-4.72), DIS: 103.82 (-1.21), BAC: 16.22 (+0.22), ORCL: 42.38 (-1.42), BRO: 31.84 (-0.02), JCI: 49.86 (-0.72), CL: 69.25 (-2.21)
Seeking Alpha's Biotech Weekly: Achillion Overdone, Sanofi's Toujeo A Go, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CYTK: 7.80 (-0.11), VRX: 198.71 (-5.24), ACT: 289.92 (-5.78), PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), CAH: 87.01 (-1.94), CLDX: 29.39 (-0.39), HSP: 87.90 (+0.05), AGN: 233.51 (-1.90), JNJ: 100.11 (-2.41), ATOS: 1.97 (-0.04), ONVO: 5.59 (-0.13), PTCT: 71.13 (-1.59), SNY: 47.42 (-0.94), PTLA: 41.72 (-0.13), INCY: 90.00 (-1.97), PFE: 33.97 (-0.50), CPHR: 11.67 (-0.33), MYL: 55.44 (-1.25), AMGN: 154.88 (-4.72), LLY: 68.41 (-2.18), BMY: 65.12 (-0.93), MNKD: 5.47 (-0.26), NKTR: 13.02 (-0.28), OMER: 26.14 (-0.21), DVA: 77.63 (+0.70), GILD: 101.81 (-1.61), SGEN: 35.32 (-0.28), ACHN: 11.39 (+0.40), MRK: 56.84 (-1.14), TEVA: 56.40 (-0.11), BIL: 45.72 (-0.01), ARIA: 8.08 (-0.17), NVS: 97.46 (-1.49)
